Pacific Biopharma Group

Pacific Biopharma is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule therapeutics for immunology and oncology. The company's lead candidate, PBG-001, is a highly selective Janus kinase 1 (JAK1) inhibitor currently in Phase 2 clinical trials for the treatment of rheumatoid arthritis and atopic dermatitis. Its pipeline also features PBG-002, a TYK2 inhibitor for autoimmune diseases, and several early-stage oncology programs targeting HPK1 and SOS1. Founded by industry veterans with a track record of successful drug development in China and globally, Pacific Biopharma aims to deliver precision medicines that address significant unmet medical needs. The company is backed by prominent life science investors and maintains operations in Hong Kong and Shanghai.